REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Eretupinab S.R.L. (Romania)

Main Activities: Residential Building Construction | Nonresidential Building Construction
Full name: Eretupinab S.R.L. Profile Updated: February 05, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Eretupinab S.R.L. is an enterprise in Romania, with the main office in BRAILA. It operates in the Residential Building Construction industry. It was first established on June 08, 2018. There are currently 13 (2025) people employed by Eretupinab S.R.L.. There was a net sales revenue increase of 23.52% reported in Eretupinab S.R.L.’s latest financial highlights for 2024. A negative growth of 47.95% was recorded in its total assets. Eretupinab S.R.L.’s net profit margin decreased by 24.06% in 2024.

Headquarters
Strada Ing. Anghel Saligny Nr. 24
BRAILA; Braila; Postal Code: 810015

Contact Details: Purchase the Eretupinab S.R.L. report to view the information.

Basic Information
Total Employees:
Purchase the Eretupinab S.R.L. report to view the information.
Registered Capital:
Purchase the Eretupinab S.R.L. report to view the information.
Financial Auditors:
Purchase the Eretupinab S.R.L. report to view the information.
Incorporation Date:
June 08, 2018
Key Executives
Purchase this report to view the information.
Administrator
Purchase this report to view the information.
Administrator
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Company Performance
Financial values in the chart are available after Eretupinab S.R.L. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RON. Absolute financial data is included in the purchased report.
Net sales revenue
23.52%▲
Total operating revenue
23.86%▲
Operating Profit/Loss (EBIT)
N/A
EBITDA
N/A
Net Profit/Loss for the Period
-1016.62%▼
Total Assets
-47.95%▼
Total Equity
-1121.44%▼
Operating Profit Margin (ROS)
N/A
Net Profit Margin
-24.06%▼
Return on Equity (ROE)
-8.62%▼
Quick Ratio
-0.31%▼
Cash Ratio
-0.14%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo